tbuckley/cabot-search huggingface dataset:
Sitting, Standing, and Walking
Authors: M. Kremer
Journal: BMJ (1958)

In the terms of the original bequest the Oliver Sharpey Lectures are required to have some physiological leaning, and physiology in the widest sense is the basis of medi- cine.A clinician, particularly a clinical neurologist, is conscious, all the time he is practising his art, that he is using the work of the physiologists and anatomists who preceded him, whether these were labelled as such or were in fact clinicians.There is now perhaps a tend- ency to swing away from the technique of meticulous
Reply
Authors: R. Willemze
Journal: British Journal of Dermatology (1986)

Journal Article Reply Get access R. Willemze R. Willemze Department of Dermatology, Free University Hospital, 1081 HV Amsterdam, The Netherlands Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 115, Issue 4, 1 October 1986, Pages 513–514, https://doi.org/10.1111/j.1365-2133.1986.tb06250.x Published: 01 October 1986
In this issue
Authors: Peter Kirkpatrick Senior, Alexandra Flemming, Charlotte Harrison, Sarah Crunkhorn Associate, Megan Cully Assistant, Katie Kingwell, Natasha Bray Senior, Mariam Faruqi, Susanne Harris, Catriona Editorial Assistants, Emily Finn, Rebecca Cromie, Judith Shadwell, Simon Fenwick, Patrick Morgan, Vicky Summersby, Natalie Smith
Journal: Nature Reviews Drug Discovery (2014)
The footballer's fracture
Journal: British Journal of Sports Medicine (1996)

CorrectionsIn the paper by Quarrie et al in the December issue (volume 29, pages263-270) there were two uncorrected errors:On page 264, right column, line 7, the sentence should read: "First class locks and loose forwards performed significantly better than did theirrespective second class peers on a vertical jump test."On page 265, right column the formula for momentum has been inverted.It should be as follows:
Clinical and Immunological Studies on a Live Attenuated Measles Virus Vaccine in Infants and Children
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mexiletine
Authors: Edward G. Abinader
Journal: JAMA (1979)

The antiarrhythmic efficacy of mexiletine hydrochloride was studied in ten selected patients with stable resistant ventricular ectopic activity in whom lidocaine, procainamide, and other antiarrhythmic agents were of no avail. Continuous Holter ECG tapes were analyzed before, during, and after mexiletine. Orally administered mexiletine was found to be very effective in treatment of drug-resistant ventricular arrhythmias, with total abolition of arrhythmia in six and satisfactory control in two additional patients. Long-term follow-up confirmed maintenance of antiarrhythmic efficacy, while biochemical and hematological screening demonstrated no abnormalities. The long therapeutic half-life of the drug allowed convenient dosage schedule and good compliance. Its efficacy, low frequency of side effects, and long half-life make it an agent of notable value in suppressing ventricular arrhythmias. (<i>JAMA</i>242:337-339, 1979)
The Risk of Suicide With Selective Serotonin Reuptake Inhibitors in the Elderly
Authors: David Juurlink
Journal: American Journal of Psychiatry (2006)

Objective: The authors explored the relationship between the initiation of therapy with selective serotonin reuptake inhibitor (SSRI) antidepressants and completed suicide in older patients. Method: The authors linked population-based coroner’s records with patient-level prescription data, physician billing claims, and hospitalization data for more than 1.2 million Ontario residents 66 years of age and older from 1992 to 2000. For each suicide case, four closely matched comparison subjects were selected using propensity score methods. The authors determined the odds ratio for suicide with SSRIs versus other antidepressant treatment, calculated at discrete monthly intervals from the start of treatment. Results: Of 1,329 suicide cases, 1,138 (86%) were each fully matched to four comparison subjects using propensity scores. During the first month of therapy, SSRI antidepressants were associated with a nearly fivefold higher risk of completed suicide than other antidepressants (adjusted odds ratio: 4.8, 95% confidence interval=1.9–12.2). The risk was independent of a recent diagnosis of depression or the receipt of psychiatric care, and suicides of a violent nature were distinctly more common during SSRI therapy. Numerous sensitivity analyses revealed consistent results. No disproportionate suicide risk was seen during the second and subsequent months of treatment with SSRI antidepressants, and the absolute risk of suicide with all antidepressants was low. Conclusions: Initiation of SSRI therapy is associated with an increased risk of suicide during the first month of therapy compared with other antidepressants. The absolute risk is low, suggesting that an idiosyncratic response to these agents may provoke suicide in a vulnerable subgroup of patients.
Error in Supplement
Journal: JAMA Network Open (2021)

Michael A. Johansson, PhD; Talia M. Quandelacy, PhD, MPH; Sarah Kada, PhD; Pragati Venkata Prasad, MPH; Molly Steele, PhD, MPH; John T. Brooks, MD; Rachel B. Slayton, PhD, MPH; Matthew Biggerstaff, ScD, MPH; Jay C. Butler, MD
MRS. CORA B. MILLER'S HOME TREATMENTAnother Fraud Put Out of Business by the Post-Office Authorities
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recent Advances in Gastroenterology
Authors: Sumner C. Kraft
Journal: JAMA (1973)

<h3>Topics in Gastroenterology 1</h3> edited by S. C. Truelove and D. P. Jewell (course, Oxford, January 1973), 323 pp, 73 illus, paper, $18.75, Blackwell Scientific Publications (F. A. Davis Co.), 1973. These new books on gastroenterology have basically similar formats, both originate from Great Britain, and each has about 15 to 20 contributors and chapters. Aside from these and other physical likenesses, however, the two volumes are rather different. With one exception, there is no overlap in authorship; and the books are not aimed at the same readers.<i>Recent Advances</i>presents subjects "slightly off the chosen beat... for the gastroenterologist." The second text is based on a recent postgraduate course primarily designed for physicians<i>not</i>specializing in gastroenterology. Except for some overlap in the rapidly expanding area of gastrointestinal immunology,<i>Topics</i>differs by placing greater emphasis on the management of commonly encountered disorders. The first edition of<i>Recent Advances</i>(1965) was
Golden Rules of Pediatrics. Aphorisms, Observations and Precepts on the Science and Art of Pediatrics. Giving Rules for Diagnosis and Prognosis, etc.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extensive bullous emphysema in a young woman
Authors: R. S. Rankin
Journal: JAMA (1976)

<h3>History</h3> A 24-year-old woman had shortness of breath of several months' duration and complained of a "cold that lasted all winter," associated with cough. She had smoked one pack of cigarettes per day for five years. Physical examination showed that she breathed through pursed lips and had distant heart sounds. Pulmonary function tests were consistent with severe obstructive airways disease. An aunt and uncle of the patient also complained of chronic dyspnea. The correct diagnosis was suggested by the roentgenologist from the routine chest films (Fig 1 and 2). <h3>Diagnosis</h3> Antitrypsin, deficiency. <h3>Comment</h3> The chest films show striking pulmonary emphysema with preferential involvement of the lower lobes (Fig 1). Bullae are evident in the anterior clear space on the lateral view (Fig 2). A pulmonary angiogram (Fig 3) demonstrates a dramatic asymmetry of perfusion between the upper and lower lung fields and verifies the severity of involvement in this young
Marriages.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ulcer Insights
Authors: Tracy Hampton
Journal: JAMA (2012)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The appropriateness of carotid endarterectomy
Authors: David W. Smith, William Stiers
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The growth in frequency of carotid endarterectomies in the United States during the 1970s and through 1984 has been documented by Dyken and Pokras.<sup>1</sup>Updated information from Veterans Administration (VA) medical centers shows that the number of carotid endarterectomies was stable from 1983 (fiscal year, starting Oct 1, 1982) through 1985, after growing at about 12% a year (compounded) for three years, or a total of about 50%, from 1980 to 1983 (Figure). In 1984 the number of procedures fell 0.2% (seven procedures) and in 1985 rose 2.2% (68 procedures). Carotid endarterectomies were done in 117 VA medical centers (172 institutions total); the 102 VA medical centers affiliated with academic medical centers performed 96% of the carotid endarterectomies. Recent professional concern<sup>2-4</sup>about complications and benefits of carotid endarterectomies could have already influenced medical decision making sufficiently to curtail the frequency of carotid endarterectomies in VA
2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol–Secondary Prevention
Authors: Scott M. Grundy, Neil J. Stone
Journal: JAMA Cardiology (2019)

This Clinical Guidelines Synopsis summarizes the 2018 American Heart Association/American College of Cardiology guidelines (secondary prevention) on management of blood cholesterol in patients at risk for atherosclerotic cardiovascular disease.
Introduction to Medicine
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oesophageal
Authors: H Li, T Walsh, T Hennessy, M Loudon, B Waldron, D Smith, P Small, F Campbell
Journal: Gut (1992)

Carcinoma arising in Barrett's oesophagus is recognized with increasing freauency but its relationship to reflux and the role of surveillance is unclear.Between 1971 and 1990, 207 patients in one unit underwent oesophagectomy for adenocarcinoma, of which 51 arose in Barrett's oesophagus, accounting for 24% of the surgically treated adenocarcinomas.The male:female ratio was 3:1 and the mean age 63.3 years.Thirteen patients (25.5%) had prior reflux symptoms; 4 patients (8%) had previous anti-reflux surgery and 2 patients were on a surveillance programme.By post-resection staging (AJCC 1988), 18 patients (35.3%) had stage II, 30 (58.8%) had stage III and 3 (5.9%)had stage IV tumours.The 90-day hospital mortality fell from 22.9% prior to 1986 to 6.3% in the past 5 years.The one, two and five-year survival rates were 45.9%, 25% and 13.6% respectively.Five-year survival was significantly greater for stage II patients (25%) than for stage III and IV patients (4.5%) (P<0.001) and for tumour length <6cm (21%) than for tumour >6cm (zero per cent) (P<0.001).The study suggests that patients with silent reflux or following reflux surgery are also at risk of malignant change.Surveillance interval is unclear as two patients developed carcinoma without prior dysplasia.Survival following resection is related to the tumour stage and tumour length and is similar to squamous cell carcinoma and adenocarcinoma without columnar metaplasia.
Chaparral Ingestion
Authors: Dafna W. Gordon
Journal: JAMA (1995)

Unconventional medical practices, including the use of herbal remedies, are prevalent in the United States. Chaparral is an herbal preparation made from a desert shrub and used for its antioxidant properties. We report the case of a 60-year-old woman who took chaparral for 10 months and developed severe hepatitis for which no other cause could be found. Despite aggressive supportive therapy, the patient deteriorated and required orthotopic liver transplantation. She is now well, more than 1 year after her transplant. This case suggests that chaparral can cause serious liver injury and fulminant hepatic failure. Herbal medications should be considered as potential causes of liver toxicity. (<i>JAMA</i>. 1995;273:489-490)
Thrombophlebitis and Pulmonary Embolism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
Authors: Ramaprasad Srinivasan, Sandeep Gurram, Munjid Al Harthy, Eric A. Singer, Abhinav Sidana, Brian M. Shuch, Mark Wayne Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy Vocke, Heidi H Kong, Edward W. Cowen, Peter L. Choyke, Ashkan A. Malayeri, Lori Long, Joanna H. Shih, Maria J. Merino, W. Marston Linehan
Journal: Journal of Clinical Oncology (2020)

5004 Background: HLRCC is a familial cancer syndrome associated with a type 2 papillary RCC (pRCC) variant. HLRCC is caused by germline mutations in the gene for the Krebs cycle enzyme fumarate hydratase (FH). FH inactivation results in VHL-independent upregulation of hypoxia inducible factor, a reliance on aerobic glycolysis, and activation of the NRF2 pathway, features also shared by some sporadic pRCC tumors. We hypothesized that the metabolic alterations underlying these tumors would be susceptible to targeted therapy with a combination of bevacizumab and erlotinib. Methods: Patients with advanced pRCC were eligible to enroll on this phase II study. To enrich for patients with FH deficiency, those with 1) HLRCC and 2) sporadic pRCC were enrolled into parallel, independent cohorts. All patients received bevacizumab 10 mg/kg IV every 2 weeks and erlotinib 150 mg orally daily. Patients who had received no more than two agents targeting the VEGFR pathway were included. Patients remained on treatment until unacceptable toxicity or progression. The primary endpoint was overall response rate (ORR); secondary endpoints were progression free survival (PFS) and duration of response. Results: A total of 83 patients with pRCC, including 42 in the HLRCC cohort and 41 in the sporadic cohort were enrolled on study. The majority of patients were IMDC intermediate risk (53/83, 64%) and 27 (33%) had at least one prior treatment. The ORR was 51% (42/83; 95% CI, 40 – 61) in all patients, 64% (27/42; 95% CI, 49 – 77) in the HLRCC cohort, and 37% (15/41; 95% CI, 24 – 52) in the sporadic cohort. The median PFS was 14.2 months (95% CI, 11.4 – 18.6) in all patients, 21.1 months (95% CI, 15.6 – 26.6) in the HLRCC cohort, and 8.7 months (95% CI, 6.4 – 12.6) in the sporadic cohort. The majority of treatment related adverse events (TRAEs) were grade 1 or 2 with the most common being acneiform rash (92%), diarrhea (77%), proteinuria (71%), and dry skin (61%). Grade ≥3 TRAEs occurred in 47% of patients, including hypertension (34%) and proteinuria (13%), with one patient (1.2%) with a grade 5 GI hemorrhage possibly related to bevacizumab. Conclusions: The combination of bevacizumab and erlotinib is well tolerated and is associated with encouraging activity in advanced pRCC, particularly in patients with FH deficient tumors. This is the first and largest prospective study in HLRCC and provides the basis for considering bevacizumab and erlotinib as a preferred option in a patient population that has no widely accepted standard. Clinical trial information: NCT01130519 .
Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3
Authors: T Egeland, R Steen, H Quarsten, G Gaudernack, YC Yang, E Thorsby
Journal: Blood (1991)